Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

摘要: The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab panitumumab) are approved clinical use. However, the percentage of patients responding to treatment low many experiencing an initial response eventually relapse. Thus, need more efficacious treatments remains. Previous studies have reported that mixtures targeting multiple distinct epitopes effective than single mAbs at inhibiting cells vitro vivo. current work describes rational approach led discovery selection novel antibody mixture Sym004, which currently Phase 2 testing. Twenty-four selected were systematically tested dual triple their ability inhibit tumor results show EGFR dependen...